Upfront combination therapy with sildenafil and ambrisentan in patients with chronic thromboembolic pulmonary hypertension
Authors:
- William Salibe-Filho1WSWilliam Salibe-Filho1
- Tulio Martins Vieira1TVTulio Martins Vieira1
- José Leonidas Alves-Junior1JAJosé Leonidas Alves-Junior1
- Yally Priscila Pessôa Nascimento1YNYally Priscila Pessôa Nascimento1
- Luiza Sarmento Tatagiba1LTLuiza Sarmento Tatagiba1
- Caio Julio Cesar Fernandes1CFCaio Julio Cesar Fernandes1
- Carlos Viana Poyares Jardim1CJCarlos Viana Poyares Jardim1
- Mario Terra-Filho1MTMario Terra-Filho1
- Rogerio Souza1RSRogerio Souza1
Open Access
- 13 September 2025
- journal article
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 51 (5) , e20250056
Abstract
Objective: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, being characterized by persistent obstruction of pulmonary vessels and leading to increased pulmonary vascular resistance and right ventricular failure. Although pulmonary endarterectomy is the preferred treatment, medical therapies may offer clinical benefits in specific settings. We sought to evaluate the clinical and hemodynamic response of CTEPH patients treated with sildenafil and ambrisentan upfront combination therapy. Methods: This was a retrospective cohort study including patients with operable and inoperable CTEPH. The patients were followed from 2019 to 2022 and were treated with sildenafil and ambrisentan as first-line therapy. Results: Functional and hemodynamic data were analyzed at baseline and after a minimum of six months of therapy. Following treatment, there was a notable improvement in functional class, natriuretic peptide levels, and invasive hemodynamics. Conclusions: The combined use of sildenafil and ambrisentan appears to be associated with clinical, functional, and hemodynamic improvement in patients with CTEPH.Keywords
This publication has 31 references indexed in Scilit:
- Long-Term Safety and Efficacy of Macitentan in Inoperable Chronic Thromboembolic Pulmonary Hypertension: Results from MERIT and its Open-Label ExtensionPulmonary Therapy, 2024
- Retraction and republication—Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled studyThe Lancet Respiratory Medicine, 2024
- Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trialThe Lancet Respiratory Medicine, 2022
- Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up studyThe Lancet Respiratory Medicine, 2022
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial HypertensionJACC, 2021
- Does combination therapy work in chronic thromboembolic pulmonary hypertension?IJC Heart & Vasculature, 2020
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2015
- Riociguat for the Treatment of Chronic Thromboembolic Pulmonary HypertensionNew England Journal of Medicine, 2013
- Incidence of Symptomatic and Asymptomatic Chronic Thromboembolic Pulmonary HypertensionArchivos de Bronconeumología, 2010
- Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary HypertensionJACC, 2008